Previous 10 | Next 10 |
Angion Biomedica ( NASDAQ: ANGN ) said Thursday that it got a letter from Nasdaq notifying that company is not in compliance with the minimum bid price requirement as per certain listing rules. The letter is only a notification of deficiency and not a notice of delisting...
UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it rece...
Angion Biomedica press release ( NASDAQ: ANGN ): Q2 GAAP EPS of -$0.30. Revenue of $0.7M misses by $0.08M . For further details see: Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M
UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and...
Angion Biomedica ( NASDAQ: ANGN ) on Monday said it had started a process to evaluate strategic alternatives, including a merger or a sale of assets. The announcement comes after the biopharmaceutical company in late June said it would discontinue its phase 2 JUNIPER trial...
UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to ...
Stifel has cut Angion Biomedica to neutral from buy following the company's decision to discontinue a phase 2 trial evaluating ANG-3070 for kidney diseases . Shares are down 36% in Thursday morning trading. The firm cut its price target to $1.50 from $5 (~12% downside ...
Gainers: NeuroSense Therapeutics ( NRSN ) +53% . Rapid Micro Biosystems ( RPID ) +36% . Burning Rock Biotech ( BNR ) +15% . Tyra Biosciences ( TYRA ) +7% . Addex Therapeutics ( ADXN ) +5% . Losers: Renalytix ( RNLX ) -40% ...
Renalytix ( RNLX ) -28% on Q3 earnings release . Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease . Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq com...
Angion Biomedica ( NASDAQ: ANGN ) on Wednesday said it would discontinue its phase 2 JUNIPER trial evaluating its inhibitor ANG-3070 for the treatment of kidney diseases. The trial is being discontinued based upon a reassessment of the risk/benefit profile of ANG-3070 ...
News, Short Squeeze, Breakout and More Instantly...
Angion Biomedica Corp. Company Name:
ANGN Stock Symbol:
NASDAQ Market:
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...
NEW YORK, NY / ACCESSWIRE / March 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ...